Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 11 participants, all of whom received an eye injection of a corticosteroid medication called triamcinolone acetonide (brand name Triesence®). Nine participants completed the study, while two did not finish. The trial was measuring changes in eye pressure, vision sharpness, retinal thickness, and the degree of cloudiness inside the eye (called vitreous haze) over a period of up to 26 weeks. The reported data shows that eye pressure (the fluid pressure inside the eye, measured in millimetres of mercury) changed by an average of −0.1 mm Hg from the starting point at week 8 — meaning it was almost unchanged. For vision sharpness, the reported data shows an average change of −0.25 units at week 8 and −0.28 units at week 26 on the scale used (where a negative number indicates an improvement in vision on that particular scoring system). Regarding retinal thickness — a measure of swelling at the centre of the retina — the reported data shows an average reduction of approximately 154 microns at week 8 and 107 microns at week 26, where a negative number indicates the retina became thinner. For vitreous haze (cloudiness inside the eye, scored on a scale where higher numbers mean more cloudiness), the reported data shows an average reduction of 0.75 score points at both week 8 and week 26. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 27980877) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a non-infectious form of uveitis (inflammation inside the eye) affecting the middle, back, or entire part of the eye
Who may not be able to join:
- You have had an injury to the eye being studied in the last 6 months
- You have received a steroid injection inside the eye, a steroid implant, or an Ozurdex® implant in the last 6 months, or have ever had a Retisert™ implant in the eye being studied
- You have an uncontrolled illness or health condition that could make it unsafe to participate in the study
- You have a known HIV infection or another condition that weakens the immune system, where steroid treatment could be harmful
- You only have one functioning eye
- You have high pressure inside your eye (a condition sometimes related to glaucoma)
- You have had any surgery inside the eye being studied at any point in the past
- You have a condition called anterior staphyloma (a thinning or bulging of the wall of the eye being studied) (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Intraocular Pressure (IOP); Best Corrected Visual Acuity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.